-+ 0.00%
-+ 0.00%
-+ 0.00%

ABBVIE HIGHLIGHTS POSITIVE RESULTS FROM THE PHASE 2 APEX PART B STUDY OF ZUMILOKIBART IN MODERATE TO SEVERE ATOPIC DERMATITIS, AS A LATE BREAKER AT EADV 2026

Reuters·09/30/2026 05:32:09